Verwandte Artikel zu National Cancer Institute Annual Report, Vol. 2: October...
National Cancer Institute Annual Report, Vol. 2: October 1, 1989, Through September 30, 1990 (Classic Reprint) - Softcover
Inhaltsangabe
Excerpt from National Cancer Institute Annual Report, Vol. 2: October 1, 1989, Through September 30, 1990
The Investigational Drug Branch (108) is responsible for sponsoring trials of new investigational drugs and of evaluating them for efficacy and toxicity. It does this by: I) Coordinating and monitoring the trials of new agents developed by the oct; 2) Planning with members of the Clinical Investigations Branch (see below overall strategies for new agent studies in specific tumor types; 3) Regulating the distribution of investigational new drugs for which oct is the sponsor; 4) Maintain close contact and ongoing dialogue with the pharmaceutical industry in an attempt to ensure that new agent development proceeds in a coordinated way.
The Clinical Investigations Branch (cib) is responsible for development and implementation of disease-oriented treatment strategies across the spectrum of human malignancies. In doing so, it provides management and oversight of the clinical cooperative group program. It manages the oncology portfolios of R01 and P01 grants.
The Regulatory Affairs Branch (rab) monitors the conduct of clinical trials performed in the nci-supported clinical trials network. It also assures that clinical investigators using experimental agents are in compliance with federal regulations regarding the use of such agents. At the start of the clinical testing of each investigational agent, rab obtains Investigational New Drug (nda) exemption authorization from the Food and Drug Administration (fda) and maintains close communication with fda in all matters relating to experimental drug studies.
About the Publisher
Forgotten Books publishes hundreds of thousands of rare and classic books. Find more at www.forgottenbooks.com
This book is a reproduction of an important historical work. Forgotten Books uses state-of-the-art technology to digitally reconstruct the work, preserving the original format whilst repairing imperfections present in the aged copy. In rare cases, an imperfection in the original, such as a blemish or missing page, may be replicated in our edition. We do, however, repair the vast majority of imperfections successfully; any imperfections that remain are intentionally left to preserve the state of such historical works.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Suchergebnisse für National Cancer Institute Annual Report, Vol. 2: October...
Foto des Verkäufers
National Cancer Institute Annual Report, Vol. 2 (Classic Reprint)
Print-on-DemandAnbieter: Forgotten Books, London, Vereinigtes Königreich
Verkäuferbewertung 5 von 5 Sternen
Paperback. Zustand: New. Print on Demand. This book presents a comprehensive analysis of the Cancer Therapy Evaluation Program (CTEP), a vital component of the National Cancer Institute (NCI). The CTEP plays a crucial role in coordinating and monitoring clinical trials for cancer treatments, ensuring the safety and effectiveness of new therapies. The author provides a detailed account of the CTEP's history, structure, and functions, highlighting its impact on cancer research and patient care. Through the examination of various case studies, the book demonstrates the CTEP's rigorous approach to clinical trial design, data analysis, and regulatory oversight. The author also explores the challenges faced by the CTEP, including the need for efficient trial designs, effective communication with the medical community, and maintaining a balance between scientific rigor and patient safety. This book serves as a valuable resource for researchers, clinicians, and policymakers involved in cancer treatment development, offering insights into the complexities and importance of clinical trial evaluation in advancing the fight against cancer. This book is a reproduction of an important historical work, digitally reconstructed using state-of-the-art technology to preserve the original format. In rare cases, an imperfection in the original, such as a blemish or missing page, may be replicated in the book. print-on-demand item. Bestandsnummer des Verkäufers 9780243586332_0
Neu kaufen
EUR 24,05
Versand gratis
Versand von Vereinigtes Königreich nach USA
Versand von Vereinigtes Königreich nach USA
Anzahl: Mehr als 20 verfügbar
Beispielbild für diese ISBN
National Cancer Institute Annual Report, Vol. 2
Anbieter: Bulrushed Books, Moscow, ID, USA
Verkäuferbewertung 4 von 5 Sternen
Zustand: Like New. In unused condition, may show some slight shelf wear, but otherwise unread. This title was digitally scanned from a rare, out of print edition, and will have some visual artifacts from that process. Bestandsnummer des Verkäufers #265E-0294
Gebraucht kaufen
EUR 28,46
EUR 8,02 Versand
Versand innerhalb von USA
Versand innerhalb von USA
Anzahl: 1 verfügbar
Beispielbild für diese ISBN
National Cancer Institute Annual Report, Vol 2 October 1, 1989, Through September 30, 1990 Classic Reprint
Anbieter: PBShop.store US, Wood Dale, IL, USA
Verkäuferbewertung 5 von 5 Sternen
PAP. Zustand: New. New Book. Shipped from UK. Established seller since 2000. Bestandsnummer des Verkäufers LW-9780243586332
Beispielbild für diese ISBN
National Cancer Institute Annual Report, Vol 2 October 1, 1989, Through September 30, 1990 Classic Reprint
Anbieter: PBShop.store UK, Fairford, GLOS, Vereinigtes Königreich
Verkäuferbewertung 5 von 5 Sternen
PAP. Zustand: New. New Book. Shipped from UK. Established seller since 2000. Bestandsnummer des Verkäufers LW-9780243586332
Neu kaufen
EUR 33,21
EUR 7,01 Versand
Versand von Vereinigtes Königreich nach USA
Versand von Vereinigtes Königreich nach USA
Anzahl: 15 verfügbar